Can I prescribe amoxicillin for pneumonia?

Amoxicillin for Pneumonia: Prescribing Recommendations

Yes, you can prescribe amoxicillin for community-acquired pneumonia (CAP), and it is the preferred first-line antibiotic for healthy outpatient adults without comorbidities or risk factors for resistant pathogens. 1

Patient Stratification and Antibiotic Selection

Healthy Outpatients Without Comorbidities

For previously healthy adults without chronic conditions, amoxicillin 1 g three times daily is the strongly recommended first-line treatment (strong recommendation, moderate quality evidence). 1

• Alternative options include doxycycline 100 mg twice daily (conditional recommendation) or macrolides only in areas where pneumococcal macrolide resistance is <25%. 1
• The FDA label confirms amoxicillin is indicated for lower respiratory tract infections due to susceptible isolates of Streptococcus pneumoniae, Streptococcus spp., Staphylococcus spp., and H. influenzae. 2

Outpatients With Comorbidities

For patients with chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; or asplenia, use combination therapy or respiratory fluoroquinolone monotherapy. 1

Combination therapy options (strong recommendation, moderate quality evidence):

• Amoxicillin-clavulanate (500/125 mg three times daily, 875/125 mg twice daily, or 2000/125 mg twice daily) PLUS a macrolide or doxycycline 1
• Alternative: Cephalosporin (cefpodoxime 200 mg twice daily or cefuroxime 500 mg twice daily) PLUS macrolide or doxycycline 1

Monotherapy option (strong recommendation, moderate quality evidence):

• Respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily, or gemifloxacin 320 mg daily) 1

Treatment Duration

For uncomplicated CAP with clinical stability achieved by day 3, a 3-day course is sufficient; if stability is achieved by day 5, treat for 5 days; otherwise, treat for 7 days for uncomplicated cases. 3

• Continue treatment for a minimum of 48-72 hours beyond when the patient becomes asymptomatic or bacterial eradication is documented. 2
• Recent evidence supports shorter courses (3-7 days) as non-inferior to longer treatments (>7 days) for uncomplicated CAP. 3

Pediatric Considerations

For children with CAP, amoxicillin remains the first-line choice, with WHO recommending a 5-day course for uncomplicated pneumonia. 4

• High-dose amoxicillin (45 mg/kg/dose every 12 hours) may be required based on local susceptibility patterns, particularly when using CLSI breakpoints. 5
• A 5-day course is as effective as 10-day treatment for uncomplicated CAP in children aged 6 months to 10 years. 6

Evidence Quality and Clinical Outcomes

Recent high-quality studies demonstrate amoxicillin's effectiveness is equivalent to broader-spectrum alternatives:

• A 2024 UK study of 16,072 pneumonia admissions found no difference in 30-day mortality between amoxicillin and co-amoxiclav (OR 1.02,95% CI 0.78-1.33), regardless of disease severity. 7
• A 2026 Swedish registry study of 34,306 primary care pneumonia cases showed no difference in hospitalization or mortality between penicillin V and amoxicillin (aOR 1.07,95% CI 0.87-1.32). 8

Important Caveats

Key considerations when prescribing amoxicillin:

• Amoxicillin is only effective against β-lactamase-negative organisms; use amoxicillin-clavulanate for suspected β-lactamase producers. 2
• Take at the start of meals to minimize gastrointestinal intolerance. 2
• Local antibiotic resistance patterns should guide therapy when available; approximately 31% of non-bacteremic pneumococcal pneumonia may be nonsusceptible to first-line outpatient agents in some US populations. 9
• Despite guideline recommendations, azithromycin remains overprescribed (47% vs. 23% for amoxicillin) in US ambulatory settings, highlighting the need for improved antibiotic stewardship. 10